shr6508
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 2022 (NCT05221008)
Timeline
Indications
Mechanism of action
- Calcium sensing receptorAGONIST
CASR agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06877247 | Phase 1 | Dec 19, 2024 | Hengrui Therapeutics, Inc. |
| NCT06434961 | Phase 3 | Jun 14, 2024 | Hengrui Therapeutics, Inc. |
| NCT06236295 | Phase 2 | Feb 20, 2024 | Hengrui Therapeutics, Inc. |
| NCT05663411 | Phase 2 | Jan 31, 2023 | Hengrui Therapeutics, Inc. |
| NCT05221008 | Phase 1 | Feb 1, 2022 | Hengrui Therapeutics, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 5 | 5 | 3 | 2022 |
1 organizations
Page 1 / 1